GSK2245035 is a selective Toll-like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 exhibits extraordinary IFNα inducing potency and IFNα/TNFα selectivity. GSK2245035 shows excellent pharmaceutical properties that allow reliable delivery of doses as low as 1 ng per actuation of an intranasal spray formulation. Intranasal GSK2245035 has an acceptable safety profile at doses that induce local TLR7-mediated immune responses. References: Tsitoura D, Ambery C, Price M, Powley W, Garthside S, Biggadike K, Quint D. Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80. doi: 10.1002/cpt.157. PubMed PMID: 26044169.

纯度：≥98%

CAS：1207629-49-9